Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0178 | 0.0145 | 0.0219 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0155 | 0.0125 | 0.0194 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00223 | -0.00285 | 0.00734 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.844 | 1.55 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.842 | 1.56 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Dulaglutide than on Placebo | 448 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Dulaglutide | 1.5 mg Dulaglutide was administered once weekly, subcutaneously | 88 | 4,949 | OG001 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo was administered once weekly, subcutaneously | 77 | 4,952 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina | ClinicalTrials.gov |
| Description | Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented. | ClinicalTrials.gov |
| Time frame | From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years) | ClinicalTrials.gov |
| Population | All randomized participants. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | ClinicalTrials.gov |
| NCT number | NCT01394952 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Cardiovascular Disease, Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | Dulaglutide, Placebo | ClinicalTrials.gov |
| Lead sponsor | Eli Lilly and Company | ClinicalTrials.gov |
| Results first posted | 2019-10-08 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01394952?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.